Seven years later, the bone was seen by the doctors drugs did in fact improve breasts cancer survival in women. PICTURES: 10 methods to tumor-proof your breasts What’s especially impressive is that the ladies were treated only one time every half a year for three years. ‘The benefit persists’ very long after treatment ends, said Dr. Michael Gnant of Austria’s Medical University of Vienna, who presented his research last week at the San Antonio Breast Cancer Symposium. Gnant’s study showed women who received the bone medication Zometa were 37 % less likely to die than females who didn’t. Which means that 4 to 5 even more women with breast tumor from every 100 were alive seven years afterwards due to the treatment.Oral BPA modified expression of HOX and WNT genes that are crucial for uterine development, they found. They are analyzing the info for the pets that received subcutaneous BPA still, Williams said. Distinctions also made an appearance in the level of advancement of the cells lining the uterine cavity in BPA-exposed animals however, not in a control band of unexposed monkeys. ‘The long-term ramifications of BPA publicity on reproductive tract advancement are unidentified,’ Williams said. ‘However, this extensive research facilitates the recommendation that women that are pregnant should limit their contact with BPA.